Article Text

Download PDFPDF

193 Edoxaban versus warfarin on stroke risk in patients with atrial fibrillation: a territory-wide cohort study
  1. Che Him Dicken Kong1,
  2. Jiandong Zhou2,
  3. Sharen Lee3,
  4. Keith Sai Kit Leung4,
  5. Tong Liu5,
  6. Abhishek C Sawant6,
  7. John Corbelli7,
  8. Abraham KC Wai8,
  9. Carlin Chang9,
  10. Qingpeng Zhang2,
  11. Gary Tse5
  1. 1Li Ka Shing Institute of Health Sciences and Chinese University Research Institute, Hong Kong, China
  2. 2School of Data Science, City University of Hong Kong
  3. 3Cardiovascular Analytics Group, Laboratory of Cardiovascular Physiology, Hong Kong
  4. 4Aston Medical School
  5. 5Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University
  6. 6Banner University Medical Center
  7. 7Buffalo VA Medical Center
  8. 8The University of Hong Kong
  9. 9Queen Mary Hospital


Background In this territory-wide, observational, propensity score-matched cohort study, we evaluate the development of transient ischaemic attack and ischaemic stroke (TIA/Ischaemic stroke) in patients with AF treated with edoxaban or warfarin.

Methods This was an observational, territory-wide cohort study of patients between January 1st, 2016 and December 31st, 2019, in Hong Kong. The inclusion were patients with i) atrial fibrillation, and ii) edoxaban or warfarin prescription. 1:2 propensity score matching was performed between edoxaban and warfarin users. Univariate Cox regression identifies significant risk predictors of the primary, secondary and safety outcomes. Hazard ratios (HRs) with corresponding 95% confidence interval [CI] and p values were reported.

Results This cohort included 3464 patients (54.18% males, median baseline age: 72 years old, IQR: 63-80, max: 100 years old), 664 (19.17%) with edoxaban use and 2800 (80.83%) with warfarin use. (Figure 1). After a median follow-up of 606 days (IQR: 306-1044, max: 1520 days), 91(incidence rate: 2.62%) developed TIA/ischaemic stroke: 1.51% (10/664) in the edoxaban group and 2.89% (81/2800) in the warfarin group. Edoxaban was associated with a lower risk of TIA or ischemic stroke when compared to warfarin (figure 2).

Conclusions Edoxaban use was associated with a lower risk of TIA or ischemic stroke after propensity score matching for demographics, comorbidities and medication use.

Conflict of Interest None

  • atrial fibrillation
  • stroke
  • edoxaban

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.